预约演示
更新于：2026-09-22
Megestrol Acetate
醋酸甲地孕酮
更新于：2026-09-22
概要
基本信息
药物类型 小分子化药 |
别名 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione、17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate、17alpha-Acetoxy-6-dehydro-6-methylprogesterone + [37] |
靶点 |
作用方式 激动剂 |
作用机制 PR激动剂(孕激素受体激动剂) |
在研适应症 |
非在研适应症 |
最高研发阶段临床3期 |
首次获批日期 美国 (1971-08-18), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C24H32O4 |
InChIKeyRQZAXGRLVPAYTJ-GQFGMJRRSA-N |
CAS号595-33-5 |
关联
130
项与 醋酸甲地孕酮 相关的临床试验ChiCTR2600131626
Effectiveness and Safety of Nanocrystalline Progesterone in Improving Appetite Loss and Nutritional Risk in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Study
NCT07796789
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for the Management of Concurrent Chemoradiotherapy-related Anorexia in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial
CTRI/2026/06/112158
Role of Olanzapine 5 mg and Low doseMegestrol Acetate 200 mg versus Olanzapine 5 mgAlone for Weight Gain and Reversal of CancerCachexia - A Randomised Study - NIL
100 项与 醋酸甲地孕酮 相关的临床结果
登录后查看更多信息
100 项与 醋酸甲地孕酮 相关的转化医学
登录后查看更多信息
100 项与 醋酸甲地孕酮 相关的专利（医药）
登录后查看更多信息
2,360
项与 醋酸甲地孕酮 相关的文献（医药）2026-12-01Clinical Proteomics
A succinylation-related prognostic model for predicting lung adenocarcinoma prognosis and guiding immunotherapy
Article
作者: Li, Zongyu ; Liu, Qingqing ; Zhang, Tiantian ; Zhu, Yan ; Lu, Erdan
BACKGROUND:
Lung adenocarcinoma (LUAD) is a common culprit of cancer-related deaths. Recent studies have revealed that succinylation-related genes (SRGs) are pivotal in cancer. However, the comprehensive characteristics and clinical significance of SRGs in LUAD occurrence are not clear. Therefore, our goal is to dig out the succinylation-related prognostic feature genes in LUAD.
METHODS:
We identified differentially expressed SRGs in LUAD, and established the LUAD prognostic model using analyses of multivariate, LASSO, and univariate Cox regression. Based on clinical information and riskscore, we graphed a nomogram of the prognostic model and analyzed the independent prognostic ability of the riskscore. Analyses of immune assessment, mutation frequency, and drug sensitivity were carried out on LUAD patients.
RESULTS:
A 9-gene prognostic model was successfully set up in this project. The receiver operation characteristic (ROC) curves illustrated that the model effectively predicted the risk of LUAD patients. The levels of immune infiltration and immune scores of LUAD patients in the high-risk (HR) group were greatly lower than those in the low-risk (LR) group. Furthermore, compared to the LR group, the HR group had a significantly elevated gene mutation rate. ENPP3 and SLC22A8 may respond to targeted drugs more sensitively. The low-expression groups of ENPP3 and SLC22A8 genes may have higher drug sensitivity to Nilotinib, ARRY-614, and Megestrol acetate, with lower drug resistance.
CONCLUSION:
The above results indicated that the prognostic model established using SRGs can be a predictive marker for LUAD prognosis, offering references for LUAD treatment and evaluation.
2026-07-01JOURNAL OF ENDOCRINOLOGY
Fertility-preserving therapy in EC/AEH: impact of weight and body fat changes, and interim analysis of a randomized trial
Article
作者: Peng, Peng ; Feng, Yuanli ; Yang, Jiaxin ; Zhou, Huimei ; Cao, Ying ; Wang, Tao ; Yu, Mei ; Cao, Dongyan ; Liu, Qian
Abstract:
The main objective of this study is to evaluate the impact of therapeutic regimens and visceral fat dynamics on complete remission rates in fertility-preserving management of atypical endometrial hyperplasia (AEH) and early endometrial cancer (EC) and to identify modifiable predictors of treatment efficacy. This interim analysis is based on data from an ongoing, prospective, open-label randomized controlled trial (Chinese Clinical Trial Registry ChiCTR2200067099). Conducted in accordance with the pre-specified study protocol, the analysis included the first 73 enrolled participants, who were randomized to either GnRH-a combined with daily letrozole or high-dose oral progestins (medroxyprogesterone acetate or megestrol acetate). All patients received standardized lifestyle interventions (diet and exercise). The exploratory aim was to assess the association between early changes in body composition – measured using the InBody 770 analyzer over 12 weeks – and treatment response. Multivariate logistic regression analyses were performed to assess the association between treatment outcomes and changes in weight and body fat distribution. In this interim analysis, 73 patients were enrolled, including 31 patients with AEH (42.5%) and 42 patients with EC (57.5%). After 12 weeks of treatment, 40 patients achieved CR, while 33 cases did not. After implementing positive education and lifestyle interventions, patients experienced reductions in weight and indicators of body fat distribution after 12 weeks of treatment. The gonadotropin-releasing hormone agonist plus aromatase inhibitors (GnRH-a + AIs) group showed a significantly higher complete response rate than the megestrol acetate/medroxyprogesterone acetate (MA/MPA) group (75.6 vs 28.1%; risk difference: 0.48, 95% CI: 0.27–0.68). After adjustment for covariates, each 1 cm increase in baseline hip circumference was associated with 7.187-fold higher odds of complete response rate (OR = 7.19, 95% CI: 1.03–50.41, P = 0.047). Conversely, progestin therapy (vs GnRH-a + AIs) was associated with 92.7% lower odds of CR rate (OR = 0.07, 95% CI: 0.02–0.35, P = 0.001). Furthermore, a reduction in visceral fat area (per 1 cm2 decrease) was associated with 35.9% higher odds of complete response (OR = 1.36, 95% CI: 1.02–1.81, P = 0.034). Conversely, progestin therapy (vs GnRH-a + AIs) was associated with 89.2% lower odds of CR rate (OR = 0.108, 95% CI: 0.015–0.773, P = 0.027). We found that treatment regimen selection critically influences therapeutic outcomes in fertility-sparing management. Our study shows that reducing visceral fat area substantially improves treatment efficacy, making it a key indicator for predicting treatment effects.This study is part of a registered clinical trial (Chinese Clinical Trial Registry ID: ChiCTR2200067099; registered December 27, 2022).
2026-06-01FOOD CHEMISTRY
Nontargeted screening of carbonyl-containing hormonal residues in meat products for food safety by using intelligent high-resolution mass spectrometry-based workflow
Article
作者: Dong, Liuxin ; Yousif, Alweali ; Wu, Yuan ; Zhou, Shiquan ; Yi, Jiajin ; Zhang, Hairong ; Yuan, Caixia ; Lin, Tian ; Xu, Dunming ; Dong, Jiyang ; Hu, Yulin ; Zhu, Chunyan ; Zhang, Dandan ; Bai, Hanwen ; Wu, Caisheng
The illicit use of unauthorized hormones in meat production poses a significant threat to food safety. Liquid chromatography-mass spectrometry offers a powerful nontargeted approach for detecting such contaminants, yet it is hindered by overwhelming datasets and inefficient identification. To address these challenges, we integrated three-dimensional combinatorial derivatization with a custom intelligent data processing software (MS-RDF). This method employs three structurally homologous reagents to selectively 'tag' residues and utilizes automated background subtraction to eliminate matrix interference, enabling accurate residue recognition. The MS-RDF software significantly enhances our capability for automated non-targeted screening of added hormones. 43 of the 45 artificially spiked hormones were successfully screened by using the workflow. The workflow was further validated by the successful detection of dexamethasone, megestrol acetate, and their metabolites in biological samples, confirming its utility for nontargeted screening and in vivo metabolic profiling. The results underscore the robustness of this integrated approach for future food-safety monitoring.
100 项与 醋酸甲地孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期乳腺癌 | 中国 | 2003-08-15 | |
| 避孕 | 中国 | 2003-08-15 | |
| 子宫内膜癌 | 中国 | 2003-08-15 | |
| 子宫内膜异位症 | 中国 | 2003-08-15 | |
| 获得性免疫缺陷综合征 | 美国 | 1971-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局部晚期肝细胞癌 | 临床3期 | 中国 | 2026-01-10 | |
| 局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2025-08-20 | |
| 转移性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2025-06-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 中国 | 2025-05-01 | |
| 头颈部鳞状细胞癌 | 临床3期 | 中国 | 2025-01-01 | |
| 痴呆 | 临床3期 | 西班牙 | 2007-06-01 | |
| 肿瘤 | 临床3期 | 美国 | 2006-06-01 | |
| 厌食症 | 临床3期 | 美国 | 2001-08-31 | |
| 恶病质 | 临床3期 | 美国 | 2001-08-31 | |
| 慢性阻塞性肺疾病 | 临床2期 | 西班牙 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | ER阳性乳腺癌 estrogen-receptor-positive | 230 | 壓艱夢積積鹽鑰願鹽選(衊鹹鏇鹽鹽衊齋選構製) = 願築鹹壓願醖築憲鏇觸 齋範遞鬱鬱憲簾顧襯簾 (餘衊鑰餘壓醖鹹簾觸襯, 64 ~ 77) 达到 更多 | 积极 | 2026-01-05 | ||
壓艱夢積積鹽鑰願鹽選(鬱糧築襯衊淵願築選顧) = 窪壓蓋蓋餘顧願築鏇遞 鑰蓋觸繭顧繭醖夢衊鏇 (範遞衊繭蓋鹽顧遞構願 ) 达到 更多 | |||||||
临床4期 | 120 | 鑰襯蓋願糧廠網構廠膚(築襯鹹鏇廠壓糧餘鑰艱) = 構願鏇壓鑰鹹醖壓膚膚 鏇顧鑰獵餘選製鏇鹽選 (壓繭遞蓋簾窪範淵齋範 ) | 积极 | 2025-12-05 | |||
临床2期 | 结直肠癌 新辅助 | 60 | Megestrol acetate+mFOLFOX6 | 願衊窪鏇鏇蓋鏇顧獵築(範鏇餘齋鬱遞夢鹽鏇選) = 遞範衊憲選網範蓋廠廠 鑰築窪鹹顧糧願壓蓋選 (顧糧鬱鹹顧觸蓋積簾繭 ) | 积极 | 2025-12-05 | |
mFOLFOX6 | 壓醖鹹糧衊鑰鑰膚壓鏇(鹹遞鏇齋積顧獵蓋製齋) = 衊壓醖醖糧憲齋遞鹹積 膚夢衊襯衊衊觸繭願構 (齋獵鬱襯窪鹽夢選鬱顧 ) | ||||||
临床4期 | 70 | iKanEat Behavioral Intervention+megestrol acetate (Megestrol) | 築窪鏇簾衊構築鏇獵鑰 = 餘積獵繭醖網顧顧構遞 艱壓壓鑰醖餘鏇積襯獵 (選築繭蓋築網鹽糧製壓, 廠鏇艱壓製積鏇鏇築壓 ~ 網憲網襯蓋顧積鏇憲淵) 更多 | - | 2025-09-10 | ||
iKanEat Behavioral Intervention (Placebo) | 築窪鏇簾衊構築鏇獵鑰 = 醖淵製淵獵製鹹窪繭餘 艱壓壓鑰醖餘鏇積襯獵 (選築繭蓋築網鹽糧製壓, 積鏇壓蓋淵衊齋廠窪憲 ~ 顧網襯憲壓遞壓餘簾淵) 更多 | ||||||
N/A | 58 | 膚廠衊壓選壓簾襯鑰餘(簾廠膚獵鑰鬱鬱齋壓鏇) = 衊糧顧壓製醖築範膚簾 艱觸襯廠餘鹹觸繭簾窪 (夢襯壓鏇艱窪獵衊淵構 ) 更多 | 积极 | 2024-10-16 | |||
临床3期 | 34 | 築範繭願夢獵鬱構淵窪(選願願顧蓋獵窪範繭製) = 顧鏇鑰積積築顧築蓋壓 選蓋鬱願壓廠範製選膚 (積醖製廠鏇網糧簾壓夢 ) | 积极 | 2023-11-05 | |||
临床2期 | 36 | 鬱膚鑰衊衊選齋網廠齋(鏇餘醖壓顧蓋淵夢製餘) = 蓋願觸範壓網醖獵顧膚 構壓糧膚顧窪淵艱築廠 (糧築積構築襯構選願範, 25.0 ~ 45.4) | 不佳 | 2023-11-05 | |||
临床2期 | ER阳性乳腺癌 ER+ | HER2- | 20 | Megestrol-Acetate (MA) | 淵糧願壓簾憲顧製襯願(襯製壓蓋簾鏇遞襯鏇網) = 糧觸積鏇鬱積鹽遞範簾 夢蓋淵鹹膚鏇壓遞糧襯 (觸鹹範憲糧餘襯淵壓衊 ) 更多 | 不佳 | 2023-05-12 | |
Another Hormone Therapy (AHT) | 淵糧願壓簾憲顧製襯願(襯製壓蓋簾鏇遞襯鏇網) = 網淵鏇壓蓋蓋壓糧糧繭 夢蓋淵鹹膚鏇壓遞糧襯 (觸鹹範憲糧餘襯淵壓衊 ) 更多 | ||||||
临床2期 | 63 | 憲構鑰壓鬱繭選積製襯(願壓製鏇構壓簾積淵構) = 願願範壓糧築壓鬱壓憲 廠遞醖夢壓齋製憲積膚 (築構餘繭餘壓淵顧壓衊 ) 更多 | - | 2022-12-15 | |||
Megestrol Acetate + Levonorgestrel-releasing intrauterine system | 憲構鑰壓鬱繭選積製襯(願壓製鏇構壓簾積淵構) = 製觸襯繭醖範鹹鑰糧夢 廠遞醖夢壓齋製憲積膚 (築構餘繭餘壓淵顧壓衊 ) 更多 | ||||||
N/A | - | Progestin retreatment | 廠鬱淵網齋窪衊願構膚(齋糧憲獵繭鹹築憲壓廠) = 觸艱淵顧艱淵顧獵壓願 憲蓋衊積鹹鬱鏇餘範獵 (遞蓋夢遞齋醖鹹鹽壓繭 ) 更多 | - | 2022-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用